NEW YORK, NY / ACCESS Newswire / February 12, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129099&wire=1 or contact Joseph E. Levi, Esq.

NATICK, Mass. , Feb. 12, 2025 /PRNewswire/ -- Cognex Corporation (NASDAQ: CGNX) today announced that the company's Board of Directors declared a quarterly cash dividend of $0.08 per share, payable on March 13, 2025 to all shareholders of record at the close of business on February 27, 2025.

Fourth Quarter 2024 Highlights Achieved net sales of $500 million, a 1% GAAP increase and 2% organic(a) increase year-over-year Generated GAAP operating income of $118 million, or 23.5% of sales, and adjusted operating income of $120 million, or 24.0% of sales Recorded GAAP net income of $88 million, or $2.22 per diluted share, and adjusted earnings of $89 million, or $2.25 per diluted share Invested $14 million for capital expenditures, repaid $43 million of debt, returned $20 million to shareholders through dividends and repurchased $10 million of common stock Full Year 2024 Highlights Achieved net sales of $1.8 billion, a …

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Grocery Outlet Holding Corp. (NASDAQ:GO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/grocery-outlet-holding-corp-lawsuit-submission-form?prid=129098&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Capri Holdings Limited (NYSE:CPRI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/capri-holdings-lawsuit-submission-form?prid=129095&wire=1 or contact Joseph E. Levi, Esq.

DAVIDSON, N.C.--(BUSINESS WIRE)--Curtiss-Wright Delivers Record FY24 Sales, Profitability, EPS, FCF & Orders; FY25 Guide 7%-8% sales growth, 17.9%-18.1% op. margin & >10% EPS growth.

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your TELUS International (Cda) Inc. (NYSE:TIXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/telus-international-lawsuit-submission-form?prid=129096&wire=1 or contact Joseph E. Levi, Esq.

NATICK, Mass. , Feb. 12, 2025 /PRNewswire/ -- Cognex Corporation (NASDAQ: CGNX) today reported financial results for the fourth quarter and full year 2024.

Record Quarterly Sales and Operating Income Revenue Grows 11% YoY with Strong Demand from Service Providers, Enterprise Customers, and U.S. Federal Agencies PLANO, Texas , Feb. 12, 2025 /PRNewswire/ -- Ribbon Communications Inc. (Nasdaq: RBBN), a prominent supplier of real-time communications technology and IP optical networking solutions, today announced its financial results for the fourth quarter and the full year of 2024. Ribbon Communications is dedicated to assisting the world's largest service providers, enterprises, and critical infrastructure operators in modernizing and safeguarding their networks and services.

NEW YORK , Feb. 12, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Grocery Outlet Holding Corp. (NASDAQ: GO) between November 7, 2023 and May 7, 2024, both dates inclusive (the "Class Period"), of the important March 31, 2025 lead plaintiff deadline. So what: If you purchased Grocery Outlet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Net income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023 $20.4 million cash balance at December 31, 2024 Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / February 12, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 second quarter.

MENLO PARK, Calif. , Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter 2024 following the close of market on Thursday, Feb. 20, 2025.

MILWAUKEE--(BUSINESS WIRE)--The Manitowoc Company, Inc. (NYSE: MTW) (the “Company” or “Manitowoc”) today reported fourth-quarter net income of $56.7 million, or $1.59 per diluted share. Fourth-quarter adjusted net income(1) was $3.7 million or $0.10 per diluted share. Orders in the quarter were $515.6 million, an 8.4% increase from the prior year. Backlog as of December 31, 2024 was $650.2 million. Net sales in the fourth quarter were relatively flat year-over-year at $596.0 million. Fourth-qua.

Study Progresses to Fourth Higher 90 mg/m 2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today provides an update from the Company's ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of refractory/relapsed acute myeloid leukemia (AML), including venetoclax-resistant patients. The Company announced a meaningful patient response to treatment and the clinical …

– Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million

JACKSONVILLE, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) announced that the Company's Board of Directors approved an eight percent increase in its quarterly dividend, from $0.12 to $0.13 per share. The new $0.13 quarterly dividend is payable on March 14, 2025, to shareholders of record at the close of business on February 28, 2025.

GLEN ALLEN, Va.--(BUSINESS WIRE)--Dynex Capital, Inc. announced today the Company's Board of Directors has declared a cash dividend of $0.15 per share on its Common Stock (NYSE: DX) for February 2025. The dividend is payable on March 3, 2025, to shareholders of record as of February 24, 2025. About Dynex Capital Dynex Capital, Inc. is a financial services company committed to ethical stewardship of stakeholders' capital; employing comprehensive risk management and disciplined capital allocation.

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein

~Revised FY2024 revenue guidance is $26.3M instead of previous guidance of $24M ~Company expects to provide Q1 ‘25 guidance in the next two weeks~ MARLBOROUGH, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- ConnectM Technology Solutions, Inc. (NASDAQ: CNTM) ("ConnectM" or the "Company"), a technology company focused on the electrification economy, today announced a significant upward revision to its previously announced Q4 2024 preliminary revenue guidance of $7 million.